期刊
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
卷 17, 期 1, 页码 29-35出版社
WILEY
DOI: 10.1111/ajco.13459
关键词
drug resistant; proteasome inhibitors; 26S proteasome
类别
Proteasome inhibitors (PIs) have been crucial therapies for myeloma patients, targeting the overstressed 26S proteasome involved in the disease pathogenesis. However, the major limitation in PI therapy lies in the acquisition of resistance, despite recent advancements in clinical antimyeloma treatment.
Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first-in-class PI, was approved by the United States Food and Drug Administration in 2003. The key roles of this class of agents are targeting at the overstressed 26S proteasome, which are involved in the pathogenesis of the disease. Despite recent advancements in clinical antimyeloma treatment, the acquisition of resistance is a major limitation in PI therapy. This review aims at a better understanding of the pathways and biomarkers involved in MM drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据